Last reviewed · How we verify
CBDV
At a glance
| Generic name | CBDV |
|---|---|
| Also known as | Cannabidivarin |
| Sponsor | King's College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) (PHASE2)
- CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) (PHASE2)
- Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder (NA)
- Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD (PHASE2)
- A Study of GWP42006 in People With Focal Seizures - Part A (PHASE2)
- A Study of GWP42006 in People With Focal Seizures - Part B (PHASE2)
- Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder (PHASE2)
- Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBDV CI brief — competitive landscape report
- CBDV updates RSS · CI watch RSS
- King's College London portfolio CI